Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Kidney International

• Publication date

  2002-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/J.1523-1755.2002.00384.XPMID 12028454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial Cells

  2001cited by this paper
• Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.

  2001cited by this paper
• Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.

  2001cited by this paper
• Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.

  2001cited by this paper
• Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.

  2000cited by this paper
• The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis.

  2000cited by this paper
• Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance

  2000cited by this paper
• Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

  1999cited by this paper
• Obesity, microalbuminuria, hyperinsulinemia, and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes.

  1999cited by this paper
• Mesangial Matrix Modulation and Glomerulosclerosis

  1999cited by this paper
• Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.

  1999cited by this paper
• A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response.

  1999cited by this paper
• Matrix Metalloproteinase-2 and Mesangiolysis in Diabetic Nephropathy

  1999cited by this paper
• PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.

  1999cited by this paper
• PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease

  1999cited by this paper
• PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.

  1998cited by this paper
• Hereditary rickets revealed.

  1998cited by this paper
• Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ

  1998cited by this paper
• Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.

  1998cited by this paper
• Mesangiolysis: an update.

  1998cited by this paper
• PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL

  1998cited by this paper
• Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma.

  1998cited by this paper
• Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1.

  1998cited by this paper
• Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats

  1998cited by this paper
• A new model of renal microvascular injury

  1998cited by this paper
• Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

  1998cited by this paper
• Compound interest: ACE and PAI-1 polymorphisms and risk of thrombosis and fibrosis.

  1998cited by this paper
• Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.

  1997cited by this paper
• Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study.

  1997cited by this paper
• Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.

  1997cited by this paper
• Vascular dysfunction in diabetes mellitus.

  1997cited by this paper
• Endothelial Function, Fibrinolysis, and Angiotensin‐Converting Enzyme Inhibition

  1997cited by this paper
• Identification of a Peroxisome Proliferator-responsive Element Upstream of the Human Peroxisomal Fatty Acyl Coenzyme A Oxidase Gene (*)

  1996cited by this paper
• The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease.

  1996cited by this paper
• Analysis of the plasminogen system on rat glomerular epithelial cells.

  1995cited by this paper
• ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.

  1995cited by this paper
• Hyperglycemia and Diabetic Kidney Disease: The Case for Transforming Growth Factor–β as a Key Mediator

  1995cited by this paper
• Molecular mechanisms of chronic renal allograft rejection.

  1995cited by this paper
• Current understanding of severe preeclampsia, pregnancy-associated hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, hemolysis, elevated liver enzymes, and low platelet syndrome, and postpartum acute renal failure: different clinical syndromes or just different names?

  1994cited by this paper
• PAI-1 and Factor VII Activity Are Higher in IDDM Patients With Microalbuminuria

  1994cited by this paper
• Expression of plasminogen/plasmin receptors on human glomerular epithelial cells.

  1994cited by this paper
• Pathophysiology of hypertensive renal damage.

  1993cited by this paper
• Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue.

  1993cited by this paper
• Mesangiolytic poststreptococcal glomerulonephritis.

  1992cited by this paper
• Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation.

  1992cited by this paper
• Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation. Evidence for involvement of macrophages and lipids.

  1991cited by this paper
• Mesangiolysis: an important glomerular lesion in thrombotic microangiopathy.

  1991cited by this paper
• The plasminogen activator/plasmin system.

  1991cited by this paper
• The mesangium in anti-Thy-1 nephritis. Influx of macrophages, mesangial cell hypercellularity, and macromolecular accumulation.

  1990cited by this paper
• Mesangiolysis in diabetic glomeruli: its role in the formation of nodular lesions.

  1988cited by this paper
• Secretory products of macrophages.

  1987cited by this paper
• [Hemolytic-uremic syndrome].

  1973cited by this paper

• Spectrum of blood viscosity, albumin/fibrinogen ratio, and red cell distribution width in newly diagnosed multiple myeloma patients: an observational study

  2025cites this paper
• Association between red blood cell distribution width to serum calcium ratio and all-cause mortality in critically ill patients with diabetic nephropathy: a retrospective analysis of the MIMIC-IV database

  2025cites this paper
• A Novel Inflammatory Marker: Relationship Between Red Cell Distribution Width/Albumin Ratio and Vascular Complications in Patients with Type 2 Diabetes Mellitus

  2024cites this paper
• Impact of diabetes mellitus and hypertension on renal function during first-line targeted therapy for metastatic renal cell carcinoma: a retrospective multicenter study

  2024cites this paper
• Role of post-translational modifications of Sp1 in cardiovascular diseases

  2024cites this paper
• Impact of Aging and Cellular Senescence in the Pathophysiology of Preeclampsia.

  2023cites this paper
• A Case of Rapidly Progressive Diabetic Nephropathy Induced by Osimertinib

  2023cites this paper
• Identification of an unrecognized circRNA associated with development of renal fibrosis

  2023cites this paper
• The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases

  2022cites this paper
• HDAC11, an emerging therapeutic target for metabolic disorders

  2022cites this paper
• GYY4137 Regulates Extracellular Matrix Turnover in the Diabetic Kidney by Modulating Retinoid X Receptor Signaling

  2021cites this paper
• The role of HDAC11 in obesity‐related metabolic disorders: A critical review

  2021cites this paper
• Glomerular endothelial cell senescence drives age‐related kidney disease through PAI‐1

  2021cites this paper
• Diabetic Kidney Disease

  2020cites this paper
• Evaluation of Diabetic Kidney Lesions

  2020cites this paper
• Nuclear receptors in podocyte biology and glomerular disease

  2020cites this paper
• Fibroblast-specific plasminogen activator inhibitor-1 depletion ameliorates renal interstitial fibrosis after unilateral ureteral obstruction.

  2019cites this paper
• Mitochondria and Chronic Kidney Disease: A Molecular Update

  2019cites this paper
• Endothelial cell-specific overexpression of endothelial nitric oxide synthase in Ins2Akita mice exacerbates diabetic nephropathy.

  2019cites this paper
• Histopathologic Study on The Toxic Effect of Aluminium Chloride on the Heart, Liver and Kidneys of Rabbits

  2018cites this paper
• Red Cell Distribution Width as a Marker of Inflammation in Type 2 Diabetes Mellitus

  2018cites this paper
• Importance of frequency and morphological characteristics of nodular diabetic glomerulosclerosis in diabetic nephropathy.

  2018cites this paper
• Coagulation and Hemostasis in Diabetic Nephropathy

  2018cites this paper
• Apolipoprotein C‐I plays a role in the pathogenesis of glomerulosclerosis

  2017cites this paper
• Interpreting Macrophage Transcripts In Human T Cell-Mediated Rejection

  2017cites this paper
• Complement Activation in Patients With Diabetic Nephropathy

  2017cites this paper
• Red cell distribution width as a significant indicator of medication and prognosis in type 2 diabetic patients

  2017cites this paper
• Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway

  2016cites this paper
• Relationship between red cell distribution width and early renal injury in patients with gestational diabetes mellitus

  2016influential citation
• An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.

  2016cites this paper
• Nephroprotective potential of Quercus infectoria galls against experimentally induced diabetic nephropathy in rats through inhibition of renal oxidative stress and TGF-β

  2016cites this paper
• Early Systemic Microvascular Damage in Pigs with Atherogenic Diabetes Mellitus Coincides with Renal Angiopoietin Dysbalance

  2015cites this paper
• Red blood cell distribution width: A simple parameter with multiple clinical applications

  2015cites this paper
• Altered Erythrocyte Glycolytic Enzyme Activities in Type-II Diabetes

  2015cites this paper
• The pathogenesis of diabetic neuropathy : a proteomic, metabolomic and electrophysiological investigation

  2015cites this paper
• Prophylactic effect of baicalein against renal dysfunction in type 2 diabetic rats.

  2014cites this paper
• A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes

  2014cites this paper
• The influence of taurine pretreatment on aluminum chloride induced nephrotoxicity in Swiss albino mice.

  2014cites this paper
• Red blood cell distribution width and diabetes-associated complications.

  2014cites this paper
• Drug Therapy Targets for Diabetic Nephropathy: An Overview

  2013cites this paper
• A Small Molecule Inhibitor to Plasminogen Activator Inhibitor 1 Inhibits Macrophage Migration

  2013cites this paper
• Neue Klassifikation der diabetischen Nephropathie

  2013cites this paper
• Glomerular mRNA Expression of Prothrombotic and Antithrombotic Factors in Renal Transplants With Thrombotic Microangiopathy

  2013cites this paper
• Neue Klassifikation der diabetischen Nephropathie

  2013cites this paper
• Effect of rosmarinic acid on experimental diabetic nephropathy.

  2012cites this paper
• Effect of loganin on experimental diabetic nephropathy.

  2012cites this paper
• Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes

  2012cites this paper
• Obesity-related glomerulopathy and podocyte injury: a mini review.

  2012cites this paper
• Histopathological changes in diabetic kidney disease

  2012cites this paper
• Fibrates: therapeutic potential for diabetic nephropathy?

  2012cites this paper
• PAI-1 mRNA expression and myocardial mircovascular change in diabetic rats: PAI-1 mRNA expression and myocardial mircovascular change in diabetic rats

  2011cites this paper
• ADAMTS13--marker of contractile phenotype of arterial smooth muscle cells lost in benign nephrosclerosis.

  2011cites this paper
• PPARγ and chronic kidney disease

  2011cites this paper
• Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus.

  2011cites this paper
• Oxidative Stress in Kidney Injury: Peroxisome Proliferator-Activated Receptor-γ Agonists Are in Control

  2011cites this paper
• Plasminogen Activator Inhibitor-1 Is a Transcriptional Target of the Canonical Pathway of Wnt/β-Catenin Signaling*

  2010cites this paper
• Pathologic classification of diabetic nephropathy.

  2010cites this paper
• PATHOPHYSIOLOGY OF DIABETIC NEPHROPATHY: AN OVERVIEW

  2010cites this paper
• Association between cardio-ankle vascular index and serum cystatin C levels in patients with cardiovascular risk factor.

  2009cites this paper
• Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis.

  2009cites this paper
• Serum lipid profile in diabetic macular edema.

  2009cites this paper
• PAI-1 and kidney fibrosis.

  2009cites this paper
• [Clinicomorphological characteristics of renal disorders in patients with genetic thrombophilia].

  2009cites this paper
• The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases

  2009cites this paper
• Effect of Astilbin on Experimental Diabetic Nephropathy in vivo and in vitro

  2009cites this paper
• The urinary proteome in diabetes and diabetes‐associated complications: New ways to assess disease progression and evaluate therapy

  2008cites this paper
• Improvement of inflammatory responses associated with NF-κB pathway in kidneys from diabetic rats

  2008cites this paper
• Rôle de l’endothélium dans les dommages radio-induits aux tissus sains

  2008cites this paper
• Relationship between peroxisome proliferator-activated receptor-γ and renal ischemia-reperfusion injury.

  2008cites this paper
• Potential for peroxisome proliferator-activated receptor-γ agonists in progression: beyond metabolism

  2008cites this paper
• Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers

  2008cites this paper
• Role of coagulation and fibrinolysis in lung and renal fibrosis.

  2008cites this paper
• Diabetic eNOS knockout mice develop distinct macro- and microvascular complications

  2008cites this paper
• Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat

  2008cites this paper
• 17beta-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling.

  2007cites this paper
• Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome.

  2007cites this paper
• Diabetes mellitus

  2007cites this paper
• PAI-1 as a target in kidney disease.

  2007cites this paper
• Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss.

  2007cites this paper
• PPAR-γ agonist protects podocytes from injury

  2007cites this paper
• Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease

  2007cites this paper
• Modulation of glomerulosclerosis

  2007cites this paper
• Common polymorphisms of the PAI1 gene do not play a major role in the development of diabetic nephropathy in Type 1 diabetes

  2007cites this paper
• PPAR-gamma agonist protects podocytes from injury.

  2007cites this paper
• Plasminogen Activator Inhibitor-1 Deficiency Has Renal Benefits but Some Adverse Systemic Consequences in Diabetic Mice

  2006cites this paper
• Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.

  2006cites this paper
• Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1.

  2006cites this paper
• Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action.

  2006cites this paper
• Biomedical Research

  2006cites this paper
• The Structure of Human Diabetic Nephropathy

  2006cites this paper
• Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 expression of glomerular mesangial cells in hypercholesterolemic rabbits.

  2006cites this paper
• Plasminogen activator inhibitor‐1 and diabetic nephropathy

  2005cites this paper
• Sesamol regulates plasminogen activator gene expression in cultured endothelial cells: a potential effect on the fibrinolytic system.

  2005cites this paper
• Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney.

  2005cites this paper
• Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.

  2005cites this paper
• PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus

  2005cites this paper
• Macrophages and progressive tubulointerstitial disease.

  2005cites this paper
• Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma.

  2005influential citation
• Posttranslational, reversible O-glycosylation is stimulated by high glucose and mediates plasminogen activator inhibitor-1 gene expression and Sp1 transcriptional activity in glomerular mesangial cells.

  2005cites this paper
• Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes.

  2005cites this paper